ASP Isotopes Inc. (NASDAQ: ASPI) has announced changes to its executive management teams, effective October 1, 2025. Paul Mann, the founder, chairman, and chief executive officer of ASP Isotopes, will become the executive chairman, taking a temporary leave of absence from his CEO duties for health reasons. In his place, Robert Ainscow, the company’s chief operating officer, has been appointed as the interim chief executive officer.
The company has also provided information on upcoming investor events, including an institutional investor access event in South Africa on November 12 and 13, 2025, and a quarterly business update in November 2025.
Additionally, Quantum Leap Energy LLC (QLE) has appointed Michael Cunniffe as its chief financial officer, effective October 1, 2025. Cunniffe brings with him extensive experience in the life science industry, having held executive roles in gene therapy companies focused on monogenetic rare diseases and early-stage pre-revenue therapeutic development start-ups.
ASP Isotopes values transparency and open communication with all stakeholders and counterparties, having welcomed over 100 investors and corporate clients to its facilities in South Africa during 2024 and 2025. The company plans to enhance its investor relations and communications by providing quarterly updates on corporate developments, with the first online presentation and Q&A session scheduled for November 2025.
ASP Isotopes, a development stage advanced materials company, is dedicated to the production of isotopes for use in multiple industries. The company employs proprietary technology, the Aerodynamic Separation Process (ASP Technology), with an initial focus on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
The company’s isotope enrichment facilities in Pretoria, South Africa, are dedicated to the enrichment of isotopes of elements with a low atomic mass. The growing demand for isotopes such as silicon-28 for quantum computing, and molybdenum-100, molybdenum-98, zinc-68, ytterbium-176, and nickel-64 for new healthcare applications, as well as chlorine-37, lithium-6, and uranium-235 for green energy applications, positions ASP Isotopes to capitalize on emerging opportunities.
In light of these changes, ASP Isotopes remains committed to executing its well-defined priorities and maintaining continuity in its corporate objectives. As a result of these announcements, the company's shares have moved 0.33% on the market, and are now trading at a price of $10.585. Check out the company's full 8-K submission here.
